All In Biotech

Drug Trial Radar · NCT07478848

Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas

A Pilot Trial of Bridging Radiation Therapy With Oral Vancomycin for Patients With B-cell Lymphomas Undergoing CAR-T Therapy

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

14

Planned (sponsor's estimate)

Start

May 29, 2026

Primary completion

Jan 1, 2029

Study completion Jan 1, 2029

Sponsor

Lead sponsor
Abramson Cancer Center at Penn MedicineAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI)
First posted
Mar 18, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical trial assesses whether it is feasible to use radiation therapy with vancomycin prior to CAR T-cell therapy for patients with large B-cell lymphomas

Conditions

  • Large B Cell Lymphoma
  • Non Hodgkin Lymphoma (NHL)
  • Diffuse Large B Cell Lymphoma (DLBCL)
  • Diffuse Large B Cell Lymphoma Refractory
  • Diffuse Large B Cell Lymphoma Relapsed

Interventions

  • Vancomycin 125mgDrug

    oral

  • Radiation TherapyRadiation

    Radiation Therapy

  • CAR-TBiological

    standard of care anti-CD19 CAR-T

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cytokine release syndromeTime frame: date of CAR-T infusion to 28 days after infusion
  2. Severe adverse eventsTime frame: CAR-T infusion to 28 days after infusion
  3. VRETime frame: start of vancomycin to day 28 after CAR-T infusion
  4. Adverse EventsTime frame: start of vancomycin until day 28 after CAR-T infusion

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Abramson Cancer Center, University of Pennsylvania

    Philadelphia, Pennsylvania · Recruiting

  • Huntsman Cancer Institute, University of Utah

    Salt Lake City, Utah · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.